Capmatinib is a selective MET inhibitor approved for the treatment of certain non-small cell lung cancers that harbor specific gene mutations. As this tyrosine kinase inhibitor is utilized in clinical… Read more









Capmatinib is a selective MET inhibitor approved for the treatment of certain non-small cell lung cancers that harbor specific gene mutations. As this tyrosine kinase inhibitor is utilized in clinical settings, pharmaceutical laboratories require high-quality reference materials to ensure the accuracy of their analytical procedures. This category provides essential reference standards, including the active pharmaceutical ingredient, known impurities such as nitrile and acid derivatives, and relevant metabolites. These compounds are critical for rigorous impurity profiling, development of stability-indicating methods, and routine quality control testing. Furthermore, stable isotope labelled compounds are available to serve as internal standards for mass spectrometry-based assays, facilitating precise quantification and method validation. By using these characterized materials, researchers can effectively monitor product quality and maintain compliance throughout the drug development lifecycle.